Cover Image
市場調查報告書

再生醫療的細胞療法市場未來

Future of Cell Therapy in the Regenerative Medicine Market

出版商 Frost & Sullivan 商品編碼 359813
出版日期 內容資訊 英文 107 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療的細胞療法市場未來 Future of Cell Therapy in the Regenerative Medicine Market
出版日期: 2016年05月25日 內容資訊: 英文 107 Pages
簡介

本報告提供全球細胞療法市場相關調查分析,以目前趨勢,預測,影響市場的外部要素為焦點,包含市場主要企業,開發中產品,聯合治療的機會,加上商業化分析等系統性資訊。

第1章 調查範圍、區分

第2章 摘要整理

第3章 創新的開發平台分析

  • 主要的手法
  • 下個細胞療法的趨勢
  • 銷售日的可能性
  • 細胞療法市場整體明細
  • 上市產品的競爭情形
  • 開發中的產品的競爭情形
  • 創新療法的可能性

第4章 市售的細胞療法產品的產品開發動態即時看板系統

  • Apligraf (Organogenesis)
  • GINTUIT (Organogenesis)
  • Grafix (Osiris Therapeutics)
  • Dermagraft (Shire)
  • Osteocel Plus (NuVasive)
  • ReCell Spray-on Skin (Avita Medical)
  • Trinity Evolution (Orthofix)
  • BioDfactor (BioD, LLC)
  • BioDfence (BioD, LLC)

第5章 值得注意的主要企業產品:各適應症

  • 現有企業的競爭概要
  • 心血管系統
  • C-Cure (Celyad)
  • Heartcel (Cell Therapy LTD)
  • MyoCell (BioHeart)
  • 免疫學
  • Prochymal (Mesoblast)
  • Cx601 (TiGenix)
  • MPC-100-IV (Remestemcel-L; Mesoblast)
  • 腫瘤學
  • NiCord (Gamida Cell)
  • StemEx (Gamida Cell)
  • ImmuniCell (TC BioPharm)
  • 肌肉骨骼系統
  • NeoCart (Histogenics)
  • NOVOCART 3D (Aesculap/B. Braun)
  • 皮膚科學
  • ALLO-ASC-DFU (Anterogen)
  • 神經學
  • MPC-06-ID (Mesoblast)

第6章 聯合治療的機會

  • 細胞遺傳基因療法
  • CTL019 (Novartis)
  • JCAR015 (Juno Therapeutics)
  • KTE-C19 (Kite Pharmaceutical)
  • 創新的技術與進步

第7章 商業化分析

  • 市場機會
  • 整體環境影響要素

第8章 商業化分析:R&D的問題

第9章 商業化分析:法規的問題

第10章 商業化分析:製造的問題

第11章 商業化分析:資金的問題

第12章 結論與要點

第13章 附錄

目錄
Product Code: P8D5-01-00-00-00

Combination Therapies and Advanced Manufacturing Techniques are the New Criteria Shaping the $4 Billion Market

Research Overview

This Frost & Sullivan research service analyses the current trends, forecasts and the external factors influencing the global cell therapy market. It also studies top participants in the market, disruptive pipeline products, and the opportunities in combination therapy. In addition, it provides a detailed commercialization analysis of research and development (R&D), manufacturing, and funding considerations.

In this research, Frost & Sullivan's expert analysts thoroughly examine the following market segments:

  • Cell-based immunotherapy
  • Stem cell therapy
  • Cell-gene therapy
  • Stem cell-gene therapy

They also analyze the following geographic segments in detail:

  • North America (Canada, the United States of America)
  • Europe (Germany, United Kingdom, Benelux, Spain, France, Scandinavia, Italy)
  • Asia-Pacific (Japan, Association of South East Asian Nations (ASEAN), China, India)
  • Rest of the world (Brazil, Africa, Russia)

Market Overview

Late Stage Hybrid Cell Therapy to Disrupt the Overall Cell Therapy Market

Heavy investments in the development and commercialization of cell therapy products have made North America the forerunner with 50 percent share in the global cell therapy market. However, the Asia-Pacific market is growing at a faster rate, on the strength of the intensified R&D activity in Japan and South Korea. Meanwhile, the pressure to reduce the cost of care for aging population has driven the governments in some countries including, Japan, Canada, and the United States to create programs to facilitate the rapid commercialization of therapy products. Accordingly, the United States and Japan have fast tracked R&D in treatments that employ highly curative stem cell, cell-gene, and immunotherapy. Many governments in North America and the Asia-Pacific are drafting policies to encourage the establishment of centers of excellence, manufacturing infrastructure and research networks to ensure profitable commercialization of products.

Despite these external drivers, the market is hindered to some extent by the lack of viable manufacturing infrastructure that supports the mass production of quality cell therapy products. Therefore, large-scale manufacturing units for autologous cell therapy and combination therapy products are necessary to meet the market demand. Manufacturers across segments could emulate the sustainable manufacturing models currently used by the market leaders to develop strategic facilities and deploy automated machinery to increase the output.

Nevertheless, the cell therapy market is growing exponentially with technical advancements in various areas. Commercializing late stage hybrid therapy will disrupt the mainstream cellular therapy market. Allogeneic therapy is expected to enjoy significant uptake as the overall market perceptibly shifts from autologous to allogeneic treatments. Market participants are also striving to find treatments for chronic diseases, with close to 50 percent of their pipeline therapy focused on oncology. Evidently, innovative treatments and sustainable manufacturing models are critical for success in this market.

Table of Contents

1. SCOPE AND SEGMENTATION

  • Scope and Segmentation
  • Key Questions this Study will Answer

2. EXECUTIVE SUMMARY

  • Key Takeaways-How is this Market Important to You?
  • Executive Summary-Market Snapshot
  • Executive Summary-Market Snapshot (continued)
  • Key 2016 Predictions-Cell Therapy Market
  • Big Market Themes for Cell Therapy
  • A Vibrant Ecosystem
  • ParadigmShift to Chronic Disease Therapies
  • Regional Highlights and Developments
  • Game-changing Companies
  • Private Investors Pour in Significant Funds

3. DISRUPTIVE PIPELINE ANALYSIS

  • Key Methodology
  • Next Wave of Cell Therapy
  • Potential Launch Dates
  • Overall Breakdown of Cell Therapy Market
  • Overall Breakdown of Cell Therapy Market (continued)
  • Competitive Landscape of Marketed Products*
  • Cell Therapy-Competitive Landscape of Products in Development*
  • Cell Therapy-Competitive Landscape of Products in Development* (continued)
  • Potential Game-changing Therapies
  • Potential Game-changing Therapies (continued)

4. PRODUCT DASHBOARD OF LEADING COMMERCIAL CELL THERAPY PRODUCTS

  • Product Dashboard-Apligraf (Organogenesis)
  • Product Dashboard-GINTUIT (Organogenesis)
  • Product Dashboard-Grafix (Osiris Therapeutics)
  • Product Dashboard-Dermagraft (Shire)
  • Product Dashboard-Osteocel Plus (NuVasive)
  • Product Dashboard-ReCell Spray-on Skin (Avita Medical)
  • Product Dashboard-Trinity Evolution (Orthofix)
  • Product Dashboard-BioDfactor (BioD, LLC)
  • Product Dashboard-BioDfence (BioD, LLC)

5. KEY COMPANIES AND PRODUCTS TO WATCH BY INDICATION

  • Competitive Overview of Established Companies
  • Cell Therapy-Cardiovascular
  • Late Stage Product Example-C-Cure (Celyad)
  • Late Stage Product Example-Heartcel (Cell Therapy LTD)
  • Late Stage Product Example-MyoCell (BioHeart)
  • Cell Therapy-Immunology
  • Late Stage Product Example-Prochymal (Mesoblast)
  • Late Stage Product Example-Cx601 (TiGenix)
  • Late Stage Product Example-MPC-100-IV (Remestemcel-L; Mesoblast)
  • Cell Therapy-Oncology
  • Late Stage Product Example-NiCord (Gamida Cell)
  • Late Stage Product Example-StemEx (Gamida Cell)
  • Late Stage Product Example-ImmuniCell (TC BioPharm)
  • Cell Therapy-Musculoskeletal
  • Late Stage Product Example-NeoCart (Histogenics)
  • Late Stage Product Example-NOVOCART 3D (Aesculap/B. Braun)
  • Cell Therapy-Dermatology
  • Late Stage Product Example-ALLO-ASC-DFU (Anterogen)
  • Cell Therapy-Neurology
  • Late Stage Product Example-MPC-06-ID (Mesoblast)

6. OPPORTUNITIES IN COMBINATION THERAPIES

  • Cell-gene Therapies and How They Work
  • Key Product Example to Watch For-CTL019 (Novartis)
  • Key Product Example to Watch For-JCAR015 (Juno Therapeutics)
  • Key Product Example to Watch For-KTE-C19 (Kite Pharmaceutical)
  • Disruptive Technologies and Advances in this Field

7. COMMERCIALIZATION ANALYSIS

  • Opportunities in this Market
  • Overall Environmental Impact Factors

8. COMMERCIALIZATION ANALYSIS-R&D CONSIDERATIONS

  • Ongoing Stem Cell Clinical Trials by Indication
  • Stem Cell Sources and Stem Cells Used in Pipeline Clinical Trials
  • Commercial Considerations for Selections of Cell Type
  • Commercial Considerations for Selections of Cell Type (continued)

9. COMMERCIALIZATION ANALYSIS-REGULATORY CONSIDERATIONS

  • Cell Therapy Regulatory Process
  • A Snapshot of Regulatory Policies for Stem Cell Therapy
  • Canada's Unique Infrastructure-Center of Excellence
  • Japan's Unique Regulatory Infrastructure

10. COMMERCIALIZING ANALYSIS-MANUFACTURING CONSIDERATIONS

  • Autologous versus Allogeneic Cell Products
  • Manufacturing Models that Work-TiGenix
  • Manufacturing Models that Work-Mesoblast
  • Manufacturing Models that Failed-Dendreon Therapeutics

11. COMMERCIALIZATION ANALYSIS-FUNDING CONSIDERATIONS

  • Funding Key Points
  • Cell Therapy Deals from 2010 to 2015
  • Funding Environment-Where are the Funds Coming From?
  • Merger, Acquisition, and Partnership Assessment
  • Merger, Acquisition, and Partnership Assessment (continued)
  • Merger, Acquisition, and Partnership Assessment (continued)
  • Merger, Acquisition, and Partnership Assessment (continued)
  • Merger, Acquisition, and Partnership Assessment (continued)
  • Merger, Acquisition, and Partnership Assessment (continued)
  • Cell Therapy Market-Funding Scenario
  • Cell Therapy Market-Funding Scenario (continued)
  • Cell Therapy Market-Funding Scenario (continued)
  • Cell Therapy Market-Funding Scenario (continued)

12. CONCLUSION AND TAKE HOME POINTS

  • Key 2016 Predictions-Cell Therapy Market
  • Key Conclusions and Future Outlook
  • Growth Opportunities in Top Segments
  • Pitfalls to Avoid
  • Legal Disclaimer

13. APPENDIX-CELL THERAPY MAJOR CLINICAL TRIAL MILESTONES

  • Cell Therapy Market-Major Ongoing/Recently Completed Clinical Trials
  • Cell Therapy Market-Major Ongoing/Recently Completed Clinical Trials (continued)
  • Cell Therapy Market-Major Ongoing/Recently Completed Clinical Trials (continued)
  • Cell Therapy Market-Major Ongoing/Recently Completed Clinical Trials (continued)
Back to Top